US Edition
Sheffield spinout Crucible Therapeutics gets £2.3m – Northern Financial Review
Summary by northernfinancialreview.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Sheffield spinout Crucible Therapeutics gets £2.3m – Northern Financial Review
University of Sheffield spinout biotech company Crucible Therapeutics has been awarded £2.3 million to develop breakthrough therapies that address underlying causes of motor neuron disease (MND). The grant from the Innovate UK Biomedical Catalyst program will support the advancement of Crucible’s differentiated siRNA program aimed at treating MND, which is also known as amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions.…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
